Guardant Health Inc (GH) – aksjekurser og nyheter

Inntekt Q3 2026 • om 3 dager

Se detaljene

GH:NASDAQ

Guardant Health Inc

170,73 USD

−4,51%

(−8,07) 1 D

171,25 USD

+0,30% (+0,52)

Etter stengetid

Stengt: 2. nov., 16:00:01 GMT-5 · USD

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for GH …

Åpne

179,50 USD

Høy

180,04 USD

Lav

167,94 USD

Markedsverdi

22,91 mrd.

Snittvolum

1,81 mill.

Volum

2,39 mill.

52 u høy

191,01 USD

52 u lav

74,55 USD

EPS

−3,50 USD

Beta

1,58

Utestående aksjer

134,20 mill.

Antall ansatte

Åpne

179,50 USD

Høy

180,04 USD

Lav

167,94 USD

Markedsverdi

22,91 mrd.

Snittvolum

1,81 mill.

Volum

2,39 mill.

52 u høy

191,01 USD

52 u lav

74,55 USD

EPS

−3,50 USD

Beta

1,58

Utestående aksjer

134,20 mill.

Antall ansatte

Relaterte aksjer

Nyhetssaker

Fra nettkilder og nyhetspartnere

Zacks

for 13 timer siden

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

for 14 timer siden

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Profil

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia

Om Guardant Health Inc

Administrerende direktørHelmy Eltoukhy | AmirAli Talasaz

Ansatte2,5k

Grunnlagt2012

HovedkontorPalo Alto, California, USA

Sektor-

Nettstedguardanthealth.com

Analytikervurderinger

Basert på 17 analytikere som har gitt aksjevurderinger for GH de siste 3 månedene

Sterkt kjøp

Kjøp

Vent

Selg

12-månedersprognose

Basert på 17 Wall Street-analytikere som har gitt 12-måneders prismål for GH de siste 3 månedene.

Høyest

Gjeldende 170,73 USD

225,00 USD (+31,79%)

Gjennomsnittlig

203,73 USD (+19,33%)

Lavest

180,00 USD (+5,43%)

Analytiker	Anbefaling	Handling	Prismål	Anslått	Dato
Mark Massaro BTIG	Buy	Maintained	210,00 USD	+23%	10/27/2026
Max Masucci Roth MKM	Buy	Initiated	200,00 USD	+17,1%	10/22/2026
Kallum Titchmarsh Morgan Stanley	Buy	Maintained	200,00 USD	+17,1%	10/20/2026
Eve Burstein Bernstein	Buy	Reiterated	210,00 USD	+23%	10/19/2026
Casey Woodring J.P. Morgan	Buy	Maintained	195,00 USD	+14,2%	10/14/2026
Lu Li Bank of America Securities	Buy	Maintained	200,00 USD	+17,1%	10/09/2026
Michael Ryskin Bank of America Securities	Buy	Maintained	200,00 USD	+17,1%	10/09/2026
Luke Sergott Barclays	Buy	Maintained	220,00 USD	+28,9%	10/07/2026
Subbu Nambi Guggenheim	Buy	Maintained	200,00 USD	+17,1%	10/01/2026
Evie Koslosky Goldman Sachs	Buy	Maintained	225,00 USD	+31,8%	09/20/2026
William Bonello Craig-Hallum	Buy	Maintained	-	-	09/15/2026
David Westenberg Piper Sandler	Buy	Maintained	193,00 USD	+13%	09/15/2026
Unknown Analyst UBS	Buy	Maintained	225,00 USD	+31,8%	09/09/2026
Doug Schenkel UBS	Buy	Maintained	225,00 USD	+31,8%	09/09/2026
Jamie Clark Rothschild & Co Redburn	Buy	Initiated	203,00 USD	+18,9%	09/08/2026
Matt Larew William Blair	Buy	Maintained	-	-	09/08/2026
Bradley Bowers Mizuho Securities	Buy	Maintained	200,00 USD	+17,1%	08/04/2026
Mason Carrico Stephens	Buy	Maintained	195,00 USD	+14,2%	08/04/2026
Kyle Mikson CFA Canaccord Genuity	Buy	Maintained	205,00 USD	+20,1%	08/02/2026
Daniel Arias Stifel Nicolaus	Buy	Maintained	180,00 USD	+5,4%	08/03/2026
Dan Leonard RBC Capital	Buy	Reiterated	200,00 USD	+17,1%	07/31/2026
Daniel Brennan TD Cowen	Buy	Reiterated	210,00 USD	+23%	07/31/2026
Brandon Couillard Wells Fargo	Buy	Maintained	125,00 USD	−26,8%	07/29/2026
Patrick B Donnelly Citi	Buy	Maintained	215,00 USD	+25,9%	07/08/2026
Vijay Kumar Evercore ISI	Buy	Maintained	200,00 USD	+17,1%	07/06/2026
Puneet Souda Leerink Partners	Buy	Reiterated	-	-	06/02/2026
Paige Chamberlain‏ Wolfe Research	Buy	Reiterated	150,00 USD	−12,1%	06/01/2026
Unknown Analyst Wolfe Research	Buy	Reiterated	150,00 USD	−12,1%	06/01/2026
Andrew Brackmann William Blair	Buy	Maintained	-	-	05/27/2026
Catherine Ramsey Schulte Robert W. Baird	Buy	Maintained	129,00 USD	−24,4%	05/08/2026
Andrew Cooper Raymond James	Buy	Reiterated	129,00 USD	−24,4%	02/23/2026

Alle verdier i USD	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	265,20 mill.	281,27 mill.	301,66 mill.	334,98 mill.
Varekostnad	93,59 mill.	99,49 mill.	104,92 mill.	115,95 mill.
Direkte driftskostnader	93,59 mill.	99,49 mill.	104,92 mill.	115,95 mill.
Utgifter til forskning og utvikling	89,96 mill.	98,26 mill.	91,04 mill.	96,53 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	180,53 mill.	204,20 mill.	227,06 mill.	250,61 mill.
Driftskostnader	270,48 mill.	302,46 mill.	318,10 mill.	347,15 mill.
Totale driftskostnader	364,07 mill.	401,96 mill.	423,02 mill.	463,10 mill.
Driftsinntekter	−98,87 mill.	−120,69 mill.	−121,35 mill.	−128,12 mill.
Andre ikke-operasjonelle inntekter	−48,00k	−4,69 mill.	1,55 mill.	308,00k
EBT inkludert uvanlige elementer	−92,59 mill.	−130,22 mill.	−111,70 mill.	−119,96 mill.
EBT uten uvanlige elementer	−92,47 mill.	−116,52 mill.	−111,70 mill.	−118,96 mill.
Kostnad for inntektsskatt	136,00k	−1,73 mill.	372,00k	185,00k
Faktisk avgiftssats	−0,15 %	1,33 %	−0,33 %	−0,15 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	−92,72 mill.	−128,49 mill.	−112,08 mill.	−120,14 mill.
Netto fortjenestemargin	−34,96 %	−45,68 %	−37,15 %	−35,87 %
Resultat per aksje	−0,39	−0,50	−0,45	−0,42
Rente- og investeringsinntekter	7,39 mill.	10,03 mill.	11,15 mill.	10,20 mill.
Rentekostnader	−943,00k	−1,18 mill.	−3,05 mill.	−1,35 mill.
Netto rentekostnader	6,45 mill.	8,85 mill.	8,10 mill.	8,85 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−89,47 mill.	−110,64 mill.	−111,91 mill.	−118,56 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

Finance

Spør om hva som helst